/Number of FDA-approved gene therapies by end of 2026
ScienceRangeEnds Dec 31, 2026
Number of FDA-approved gene therapies by end of 2026
The FDA has approved a handful of gene therapies since 2017. A pipeline of sickle-cell, hemophilia, and rare-disease treatments are in late-stage review.
Price Ranges
5Volume
$1.36M
Traders
9.4K
Liquidity
$280K
Outcomes
5
Trade
Select an outcome from the list to start trading
$
You Pay—
Fee (1%, incl.)—
Trade Amount—
Shares—
Current Price—
Max Payout—
Max profit if correct—
Mock mode — no real funds used
Market Rules
Description
The FDA has approved a handful of gene therapies since 2017. A pipeline of sickle-cell, hemophilia, and rare-disease treatments are in late-stage review.
This is a range market. Each range represents a price bracket. Buy shares in the range you believe will contain the final value. Only one range can resolve as correct.